Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout

"We will introduce the 2.4 milligram pemvidutide dose in Phase III," Arbet-Engels said (Chief Medical Officer), describing PERFORMA as "an event-driven study" with "the interim analysis" at "52 weeks ...
Cantech Letter

Euro Manganese Announces Positive Preliminary Economic Assessment

EMN Responds to Market with Solid Economics, Increased Recoveries, and New Commercial Plant Optionality Vancouver, British Columbia–(Newsfile Corp. – May 14, 2026) – Euro Manganese Inc. (TSXV: ...